ProKidney to Participate in Fireside Chat at the Jefferies Healthcare Conference
01 Juin 2023 - 10:05PM
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the
“Company”), a leading late clinical-stage cellular therapeutics
company focused on chronic kidney disease (CKD), today announced
that Dr. Tim Bertram, Chief Executive Officer, will participate in
a fireside chat at the
Jefferies Healthcare
Conference, being held in New York, NY from June 7 – 9,
2023.
Dr. Bertram’s session is scheduled for Thursday,
June 8, at 4:00 pm ET. A live webcast will be available on the
Events and Presentations section of ProKidney’s investor relations
website at
https://investors.prokidney.com/news-events/events-and-presentations.
Investors attending the conference and
interested in meeting with ProKidney management may request a
meeting by contacting their Jefferies representative.
About ProKidneyProKidney, a pioneer in the
treatment of CKD through innovations in cellular therapy, was
founded in 2015 after a decade of research. ProKidney’s lead
product candidate, REACT® (Renal Autologous Cell Therapy), is
a first-of-its-kind, patented, proprietary autologous cellular
therapy with the potential to preserve kidney function in patients
at high risk of kidney failure. Late-stage CKD patients, Stage 3b -
4, are a key target population for REACT therapy. REACT has
received Regenerative Medicine Advanced Therapy (RMAT) designation,
as well as FDA and EMA guidance, supporting its ongoing Phase 3
clinical program that launched in January 2022. For more
information, visit www.prokidney.com.
About CKDCKD is a serious diagnosis with
significant morbidity and mortality. Notably, the 5-year mortality
of newly diagnosed Stage 4 CKD is higher than that of newly
diagnosed non-metastatic cancer. CKD most often presents as a
progressive decline in kidney function, ultimately resulting in the
failure of the kidneys and the need for renal replacement therapy,
such as hemodialysis or kidney transplant. One in three Americans
is at risk for CKD, which currently affects approximately 75
million people in the United States and Europe and over 400 million
across Asia. CKD is among the largest single expense incurred by
the U.S. health care system.
Forward-Looking StatementsThis press release
includes “forward-looking statements” within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995. ProKidney’s actual results may differ from its
expectations, estimates and projections and consequently, you
should not rely on these forward-looking statements as predictions
of future events. Words such as “expect,” “estimate,” “project,”
“budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,”
“will,” “could,” “should,” “believes,” “predicts,” “potential,”
“continue,” and similar expressions (or the negative versions of
such words or expressions) are intended to identify such
forward-looking statements. These forward-looking statements
include, without limitation, the Company’s expectations with
respect to financial results and expected cash runway, future
performance, development and commercialization of products, if
approved, the potential benefits and impact of the Company’s
products, if approved, potential regulatory approvals, the size and
potential growth of current or future markets for the Company’s
products, if approved, the advancement of the Company’s development
programs into and through the clinic and the expected timing for
reporting data, the making of regulatory filings or achieving other
milestones related to related to the Company’s product candidates,
and the advancement and funding of the Company’s developmental
programs generally. Most of these factors are outside of the
Company’s control and are difficult to predict. Factors that may
cause such differences include, but are not limited to: the
inability to maintain the listing of the Company’s Class A ordinary
shares on the Nasdaq; the inability to implement business plans,
forecasts, and other expectations or identify and realize
additional opportunities, which may be affected by, among other
things, competition and the ability of the Company to grow and
manage growth profitably and retain its key employees; the risk of
downturns and a changing regulatory landscape in the highly
competitive biotechnology industry; the inability of the Company to
raise financing in the future; the inability of the Company to
obtain and maintain regulatory clearance or approval for its
products, and any related restrictions and limitations of any
cleared or approved product; the inability of the Company to
identify, in-license or acquire additional technology; the
inability of Company to compete with other companies currently
marketing or engaged in the biologics market and in the area of
treatment of kidney diseases; the size and growth potential of the
markets for the Company’s products, if approved, and its ability to
serve those markets, either alone or in partnership with others;
the Company’s estimates regarding expenses, future revenue, capital
requirements and needs for additional financing; the Company’s
financial performance; the Company’s intellectual property rights;
uncertainties inherent in cell therapy research and development,
including the actual time it takes to initiate and complete
clinical studies and the timing and content of decisions made by
regulatory authorities; the fact that interim results from our
clinical programs may not be indicative of future results; the
impact of COVID-19 or geo-political conflict such as the war in
Ukraine on the Company’s business; and other risks and
uncertainties included under the heading “Risk Factors” in the
Company’s most recent Annual Report on Form 10-K, subsequent
Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. The Company cautions readers
that the foregoing list of factors is not exclusive and cautions
readers not to place undue reliance upon any forward-looking
statements, which speak only as of the date made. The Company does
not undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions or circumstances on which any such statement is
based.
Contacts:
Corporate:Glenn Schulman,
PharmD, MPHSVP, Investor Relationsglenn.schulman@prokidney.com
Investors:Burns McClellanLee
RothLroth@burnsmc.com
Media:Burns McClellanSelina
Husain / Robert Flamm, Ph.D.shusain@burnsmc.com /
rflamm@burnsmc.com
ProKidney (NASDAQ:PROK)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
ProKidney (NASDAQ:PROK)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024